Resources

Moxidectin for Onchocerciasis - Current Status and Next Steps Towards Implementation

October 2022

Learn about our latest Annual Report, attendance at ASTMH annual meeting, signing of the Kigali Declaration, job opportunities and more.

March 2022

Learn about progress in clinical development, team expansion, awards and more.

‍

Our 2021 Annual Report documents our medicine development progress, highlights our achievements over the year, and presents our approach to looking forward and continuing our global presence.

December 2021

Learn about new lymphatic filariasis data for moxidectin, progress in clinical development, team expansion, awards and more.

‍

September 2021

Learn about MDGH's expanded footprint, its progress in clinical development, a social impact investment opportunity, and the nominations for the Prix Galien Award for 2021

Moxidectin in Onchocerciasis: Ongoing Clinical Trial Protocols: MDGH-MOX-3001: Safety and efficacy of annual or biannual doses of moxidectin or ivermectin for onchocerciasis​ (Target: approx. 1,000 participants)​.

Moxidectin in Onchocerciasis: Ongoing Clinical Trial Protocols: MDGH-MOX-3002: Safety of a single dose of moxidectin compared with ivermectin in individuals living in onchocerciasis-endemic areas (Target: approx. 12,500 participants).

June 2021

A look at the 2020 MDGH Annual Report, clinical development updates, and the development of a new formulation of moxidectin for children.

March 2021

Learn more about MDGH's plans for its new investigational treatment for tuberculosis and leprosy types 2 reactions.

MDGH celebrated its 15th anniversary in 2020. Our 2020 Annual Report documents our progress as well as our current thinking on our contribution to neglected disease R&D and access to medicines.

Opoku NO, Bakajika DK, Kanza EM, et al. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. Lancet. 2018;392(10154):1207-1216

Korth-Bradley JM, Parks V, Chalon S, et al. Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women. Antimicrob Agents Chemother.2011;55(11):5200-5204.

Kinrade SA, Mason JW, Sanabria CR, et al. Evaluation of the cardiac safety of long-acting endectocide moxidectin in a randomized concentration-QT study. Clin Transl Sci. 2018;11(6):582-589.

Korth-Bradley JM, Parks V, Patat A, Matschke K, Mayer P, Fleckenstein L. Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin. Clin Pharmacol Drug Dev. 2012;1(1):32-37.

Turner HC, Walker M, Attah SK, et al. The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data. Parasit Vectors. 2015;8:167.

Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis. 2014;8(6):e2953.

Milton P, Hamley JID, Walker M, Basanez MG. Moxidectin: an oral treatment for human onchocerciasis. Expert Rev Anti Infect Ther. 2020:1-15. 10.1080/14787210.2020.1792772

Boussinesq M, Fobi G, Kuesel AC. Alternative treatment strategies to accelerate the elimination of onchocerciasis. Int Health. 2018;10(suppl_1):i40-i48.